Evidence map›Paper›PMID 42738389›Full record

ArticleCancers2026

Real-World Treatment Patterns and Clinical Outcomes After First-Line Therapy in Patients with KRAS G12C-Mutant Advanced Non-Small-Cell Lung Cancer in the United States.

Kristin M Sheffield, Tarun Puri, Kelli Thoele, Himanshu Karu, Arti Mansharamani, Dipesh Uprety

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kristin M SheffieldEli Lilly and Company, Indianapolis, IN 46285, USA.
Tarun PuriEli Lilly and Company, Indianapolis, IN 46285, USA.ORCID 0000-0003-2399-4362
Kelli ThoeleEli Lilly and Company, Indianapolis, IN 46285, USA.ORCID 0000-0003-0084-5698
Himanshu KaruEli Lilly and Company, Indianapolis, IN 46285, USA.
Arti MansharamaniEli Lilly and Company, Indianapolis, IN 46285, USA.
Dipesh UpretyMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

backgroundApproximately 13% of NSCLC cases have

methodsThis retrospective study used data from two US nationwide databases, an electronic health records (EHR) database and a clinico-genomic database (CGDB) of EHR data linked to data from comprehensive genomic profiling tests. Eligible patients had advanced NSCLC, initiated first-line therapy from August 2018 to December 2022, and had

resultsThere were 1227 patients with

conclusionsThese data provide a real-world benchmark of outcomes for patients with

Indexed as

KRAS G12Cnon-small-cell lung cancerpatient characteristicsreal-world outcomesunmet need

Identifiers

PMID42738389
PMCPMC13565047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.